CDXC
Price
$5.94
Change
+$0.29 (+5.13%)
Updated
Jan 17 closing price
Capitalization
453.72M
46 days until earnings call
MDGL
Price
$293.64
Change
+$20.85 (+7.64%)
Updated
Jan 17 closing price
Capitalization
6.4B
39 days until earnings call
Ad is loading...

CDXC vs MDGL

Header iconCDXC vs MDGL Comparison
Open Charts CDXC vs MDGLBanner chart's image
ChromaDex
Price$5.94
Change+$0.29 (+5.13%)
Volume$364.99K
Capitalization453.72M
Madrigal Pharmaceuticals
Price$293.64
Change+$20.85 (+7.64%)
Volume$866.12K
Capitalization6.4B
CDXC vs MDGL Comparison Chart
Loading...
CDXC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXC vs. MDGL commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXC is a Hold and MDGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CDXC: $5.94 vs. MDGL: $293.64)
Brand notoriety: CDXC and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXC: 56% vs. MDGL: 221%
Market capitalization -- CDXC: $453.72M vs. MDGL: $6.4B
CDXC [@Biotechnology] is valued at $453.72M. MDGL’s [@Biotechnology] market capitalization is $6.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXC’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CDXC’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than CDXC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXC’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 3 bullish TA indicator(s).

  • CDXC’s TA Score: 4 bullish, 4 bearish.
  • MDGL’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CDXC is a better buy in the short-term than MDGL.

Price Growth

CDXC (@Biotechnology) experienced а +12.71% price change this week, while MDGL (@Biotechnology) price change was -13.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

CDXC is expected to report earnings on May 08, 2025.

MDGL is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.4B) has a higher market cap than CDXC($454M). CDXC YTD gains are higher at: 11.970 vs. MDGL (-4.838). CDXC has higher annual earnings (EBITDA): 1.95M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. CDXC (32.2M). CDXC has less debt than MDGL: CDXC (2.9M) vs MDGL (119M). CDXC has higher revenues than MDGL: CDXC (91.7M) vs MDGL (76.8M).
CDXCMDGLCDXC / MDGL
Capitalization454M6.4B7%
EBITDA1.95M-502.65M-0%
Gain YTD11.970-4.838-247%
P/E Ratio297.00N/A-
Revenue91.7M76.8M119%
Total Cash32.2M999M3%
Total Debt2.9M119M2%
FUNDAMENTALS RATINGS
CDXC vs MDGL: Fundamental Ratings
CDXC
MDGL
OUTLOOK RATING
1..100
1319
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
8530
SMR RATING
1..100
8499
PRICE GROWTH RATING
1..100
3550
P/E GROWTH RATING
1..100
55100
SEASONALITY SCORE
1..100
5049

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (68) in the Pharmaceuticals Other industry is in the same range as CDXC (94) in the Chemicals Specialty industry. This means that MDGL’s stock grew similarly to CDXC’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is somewhat better than the same rating for CDXC (85) in the Chemicals Specialty industry. This means that MDGL’s stock grew somewhat faster than CDXC’s over the last 12 months.

CDXC's SMR Rating (84) in the Chemicals Specialty industry is in the same range as MDGL (99) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to MDGL’s over the last 12 months.

CDXC's Price Growth Rating (35) in the Chemicals Specialty industry is in the same range as MDGL (50) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to MDGL’s over the last 12 months.

CDXC's P/E Growth Rating (55) in the Chemicals Specialty industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXCMDGL
RSI
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
76%
Bearish Trend 5 days ago
83%
Momentum
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
87%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 5 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 5 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 5 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 5 days ago
80%
Aroon
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 5 days ago
77%
View a ticker or compare two or three
Ad is loading...
CDXC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

CDXC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXC has been loosely correlated with AKBA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXC jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXC
1D Price
Change %
CDXC100%
+5.13%
AKBA - CDXC
34%
Loosely correlated
+7.25%
MDGL - CDXC
31%
Poorly correlated
+7.64%
GBIO - CDXC
26%
Poorly correlated
+0.18%
BDTX - CDXC
26%
Poorly correlated
-0.45%
CRSP - CDXC
25%
Poorly correlated
+0.57%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ETNB. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+7.64%
ETNB - MDGL
41%
Loosely correlated
+3.53%
CRSP - MDGL
36%
Loosely correlated
+0.57%
AKRO - MDGL
35%
Loosely correlated
+4.71%
BEAM - MDGL
33%
Poorly correlated
+0.17%
CDXC - MDGL
31%
Poorly correlated
+5.13%
More